Indication: Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Sub-indication: Low-Grade Glioma (LGG)
Study Type: Drug Study
Principal Investigator: Ashok Raj, M.D.Norton Children's Cancer Institute, affiliated with the UofL School of Medicine
Sponsor: Sponsor: Children's Oncology Group (COG)
